Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

<p>Abstract</p> <p>Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous dr...

Full description

Bibliographic Details
Main Authors: Gadó Klára, Matolcsy András, Csomor Judit, Kicsi Dóra, Bödör Csaba, Domján Gyula
Format: Article
Language:English
Published: BMC 2012-07-01
Series:Experimental Hematology & Oncology
Subjects:
Chronic myeloid leukemia
Dasatinib
Imatinib
Tyrosine kinase inhibitor
Drug intolerance
Online Access:http://www.ehoonline.org/content/1/1/17

Internet

http://www.ehoonline.org/content/1/1/17

Similar Items